SONIO
20.12.2022 09:31:44 CET | Business Wire | Press release
Sonio announces a €10M fundraising through the European Innovation Council Accelerator, the leading fund in supporting European deep-tech companies. For this cohort, among 1092 projects submitted, only 78 companies were selected by the EIC Accelerator. This fundraising (€2.5M in grant and €7.5M in equity investment) comes in addition to the €5M previously raised with Elaia, OneRagtime and Bpi France in June 2022. It will support Sonio, a company that empowers fetal medicine professionals and secures pregnancy ultrasounds through AI, to accelerate the release of new features on the platform, such as embedded image recognition and genomics. A great opportunity, also, to gain momentum for the French startup’s market entry in the USA, as well as ramp up sales in Europe and India.
Sonio brings together unique expertise from the fields of fetal medicine, artificial intelligence, software development and ultrasound imaging to address the 50% of congenital malformations that are not detected before birth and improve access and quality of care for pregnant women and children. Created only a couple of years ago, the startup company leverages 5 years of R&D and clinical development at Ecole Polytechnique, the PRAIRIE Institute and Necker Hospital in Paris. It already provides a comprehensive solution to assist all fetal ultrasound practitioners, from beginners to the most seasoned experts and is already being used by over 250 healthcare professionals.
“Receiving such a significant funding from one of the most competitive accelerators in the world is a testament to the innovation Sonio brings to fetal medicine” said Cécile Brosset, Chief Executive Officer and co-Founder of Sonio. « Our hard work has been fruitful. I am now more confident than ever that we can help secure pregnancy care worldwide with collective and artificial intelligence.”
“For us this funding means more research, more clinical studies, more innovation, more patents filed in Europe and ultimately an improved quality of care for patients, wherever they are. We are eager to intensify our scientific partnerships with some of the best experts in Fetal Medicine and Artificial Intelligence.” said Rémi Besson, Chief Scientific Officer and co-Founder of Sonio.
Inspired by the company’s mission and in just 2.5 years, Sonio’s multidisciplinary team has already brought 2 products to market:
- Sonio Diagnostics, designed for expert diagnostic ultrasounds, was CE marked and found its first clients in record time.
- Sonio Pro, tailored to secure and bring more efficiency to routine pregnancy ultrasounds, was launched in October and has already convinced customers in Europe.
Several partnerships have already been signed, with Samsung France, one of the main women’s health ultrasound manufacturers, but also with specialized distributors (Lifecell in India, Manager Systems in Brazil, Dynamic Medicals in Nigeria).
“This funding from EIC will allow us to accelerate our commercial development in the USA and in Europe, thanks to faster innovation and better market access. We will also be able to initiate more distribution partnerships in countries where access to healthcare is scarce, thus helping us to fulfill our mission, which is to improve access and quality of care of women and children.” said Dagmar Nuber, Chief Business Officer and co-Founder at Sonio.
About Sonio
Founded in 2020, Sonio is the only SaaS platform that empowers healthcare professionals to secure prenatal care by combining technological innovation, medical expertise, and collective intelligence. It provides a unique Artificial Intelligence software that associates the knowledge of prenatal medicine practitioners with all types of medical, imaging, genetic and environmental data to optimize prenatal screening and diagnosis.
Created by a team of entrepreneurs, and scientific, medical and tech experts, Sonio is already used by over 250 healthcare professionals.
Sonio is committed to become an “Entreprise à Mission” – a company whose objectives in the social, societal, and environmental fields are aligned with this purpose and set out in its by-laws, as defined by the 2019 PACTE law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005108/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 08:00:00 CET | Press release
Acquisition combines Yamaha’s audio expertise with Disguise’s software and media server technologies Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into software and services. By combining Yamaha’s audio expertise and global reach with Disguise’s software, technologies and worldwide partner network, the companies will be better positioned to deliver immersive experiences across live entertainment, sports and other venues. Disguise’s technology powers live and immersive experiences worldwide, including tours by Beyoncé and Taylor Swift and venues such as New York’s
Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane® Shaype™ for Both Chin and Its First Jawline Indication13.11.2026 07:00:00 CET | Press release
Restylane Shaype is now approved in Mexico for temporary augmentation in the chin area and improvement of jawline definition,1 with launch anticipated in H1 2027 Already approved across various markets globally for the chin area,2 this marks Restylane Shaype’s first approval for the jawline worldwide1 The first-and-only shaper on the hyaluronic acid (HA) market, Restylane Shaype features the firmest HA gel available and is powered by proprietary NASHA HD™ technology, developed to build and shape on bone for instant, natural-looking contour and definition3-6 The approval reinforces Galderma's commitment to advancing innovation in the HA category, enabling the company to meet diverse patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expan
vVARDIS Announces Pricing of Initial Public Offering13.11.2026 06:02:00 CET | Press release
vVARDIS Holding AG (“vVARDIS”), a Swiss healthcare company operating in the dental med-tech sector, today announced the pricing of its initial public offering of 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. In connection with the offering, vVARDIS has granted the underwriters a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares at the initial public offering price to cover over-allotments. The Class A ordinary shares are expected to begin trading on the New York Stock Exchange on November 13, 2026 under the symbol “VVVV.” The closing of the offering is expected to occur on or about November 16, 2026 subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint bookrunning managers for the offering, with William Blair, UBS Investment Bank and Deutsche Bank Securities acting as bookrunners. A registration statement on Form F-1 relating to the offering has been file
Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*12.11.2026 23:07:00 CET | Press release
The multi-level takeover includes a Throne Room, interactive photo opportunities, special lighting, and more The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 18:09:00 CET | Press release
Veristat’s InStat™ delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom